Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment

Clinical Microbiology and Infection

Volumn 11, Issue 6, 2005, Pages 466-471

  Wernitz, Martin H ^a   Keck, S ^b   Swidsinski, S ^b   Schulz, S ^b   Veit, S K ^a  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^b Becton Dickinson GmbH Germany   (Germany)

Author keywords

Cost effectiveness; Diagnosis related groups payment; Hospital acquired infection; MRSA; Screening programme

Indexed keywords

METICILLIN;

ANTIBIOTIC RESISTANCE; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; GERMANY; HOSPITAL INFECTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; SCREENING; SENSITIVITY ANALYSIS; STAPHYLOCOCCUS INFECTION;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 19744363892     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01153.x     Document Type: Article

References (19)

1. Anonymous. European Antimicrobial Resistance Surveillance System. EARSS Annual Report. Bilthoven: EARSS 2001.
2. Tiemersma ET, Bronzwaer S, Lyytikäinen O et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002 Emerg Infect Dis 2004; 10: 1627-1634.
3. Rosdahl VT, Knudsen AM. The decline of methicillin resistance among Danish Staphylococcus aureus strains. Infect Cont Hosp Epidemiol 1991; 12: 83-88.
4. Girou E, Pujade G, Legran P, Cizeau F, Brun-Buisson C. Selective screening for carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clin Infect Dis 1998; 27: 543-550.
5. Papia G, Louie M, Tralla A, Johnson C, Collins V, Simor AE. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Cont Hosp Epidemiol 1999; 20: 473-477.
6. Wernitz MH, Swidsinski S, Weist K et al. Effectiveness of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers at hospital admission to prevent hospital-acquired MRSA infections. Clin Microbiol Infect 2005; 11: 457-465.
7. Stone PW, Larson E, Kawar LN. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Cont 2002; 30: 145-152.
8. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost and prevention. Infect Cont Hosp Epidemiol 1996; 17: 552-557.
9. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian Hospitals. Infect Cont Hosp Epidemiol 2001, 22: 99-104.
10. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Cont Hosp Epidemiol 1999; 20: 408-411.
11. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with surgical site infection. Clin Infect Dis 2003; 36: 592-598.
12. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus. A cost-benefit analysis in an intensive care unit. JAMA 1999; 282: 1745-1751.
13. Jernigan JA, Clemence MA, Stott GA et al. Control of methicillin-resistant Staphylococcus aureus at a University hospital: one decade later. Infect Cont Hosp Epidemiol 1995; 16: 686-696.
14. Wenzel RP. Nosocomial infections, diagnosis-related groups, and study on the efficacy of nosocomial infection control. Economic implications for hospitals under the prospective payment system. Am J Med 1985; 78: 3-7.
15. Haley RW, White JW, Culver DH, Hughes JM. The financial incentive for hospitals to prevent nosocomial infections under the prospective payment system. An empirical determination from a nationally representative sample. JAMA 1987; 257: 1611-1614.
16. Boyce JM, White RL, Spruill EY. Impact of methicillin-resistant Staphylococcus aureus on the incidence of nosocomial staphylococcal infections. J Infect Dis 1983; 148: 763.
17. Stamm AM, Long MN, Belcher B. Higher overall nosocomial infection rate because of increased attack rate of methicillin-resistant Staphylococcus aureus. Am J Infect Cont 1993; 21: 70-74.
18. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchner AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteriaemia: a meta-analysis. Clin Infect Dis 2003; 36: 53-59.
19. Whitby M, McLaws M-L, Berry G. Risk of death from methicillin resistant Staphylococcus aureus bacteriaemia: a meta-analysis. Med J Aust 2001; 175: 264-267.